• Channels
    • All News
    • Premium Stories
    • R&D
    • Pharma
    • Venture
    • People
    • Startups
    • Regulatory
    • Deals
    • IPOs
    • China
    • Cell/Gene Tx
    • Bioregnum
    • Peer Review
    • Discovery
    • Outsourcing
    • AI
    • Special
  • Events
  • Biopharma Jobs
  • More
    • Webinars
    • Sponsored Posts
    • Biotech Voices
    • Advertise
    • Privacy Policy
    • About Us
    • Help
  • SUBSCRIBE

Near­ly a year af­ter sur­prise re­jec­tion, Im­munomedics re­turns to FDA

6 days ago
R&D

Cell, gene ther­a­py man­u­fac­tur­ing takes cen­ter stage as No­var­tis, Ama­zon join forces

6 days ago
R&D

FDA will con­vene ad­comm for Bris­tol-My­er­s' Re­blozyl in MDS; FDA grants 'or­phan' tags to a trio of drugs

6 days ago
Protocols

Mer­ck in $1.3B show­down with in­sur­ers over 2017 ran­somware at­tack — Bloomberg

6 days ago
R&D

Ea­ger to tout piv­otal win, Omeros how­ev­er keeps key pa­ra­me­ters shroud­ed

6 days ago
R&D

As it shops for new deals, Akcea hires for­mer GSK ex­ec as COO

6 days ago
People
R&D

In a win for in­dus­try, Trump ad­min­is­tra­tion is­sues scathing re­view of Pelosi drug pric­ing bill

6 days ago
Pharma

An old, con­tro­ver­sial Pfiz­er drug shows mid-stage ef­fi­ca­cy against nar­colep­sy

6 days ago
R&D

Roche moves deep­er in­to Mer­ck ter­ri­to­ry with Tecen­triq/chemo OK in front­line NSCLC

6 days ago
Pharma

An­ti­body strat­e­gy to aug­ment ver­sa­tile im­mune cells sparks in­vest­ment in French biotech

Last week
Startups
Venture

Bio­gen comes un­der re­newed fire as a lead­ing Alzheimer's ex­pert rais­es se­ri­ous ques­tions about the ad­u­canum­ab da­ta

Last week
People
R&D

RAPT signs on with strug­gling Han­mi for Asian en­trance of can­cer ther­a­py aimed at 'charged tu­mors'

Last week
Deals

Arde­lyx reach­es the 'cap­stone' in their third-straight pos­i­tive PhI­II – but many ques­tions still linger

Last week
R&D

Ab­b­Vie picks first Alzheimer's, Parkin­son's tar­gets in Mis­sion pact; Amarin files for Vas­cepa OK in Eu­rope

Last week
Protocols

Bio­gen boasts PhII win in lu­pus — will any­one turn their head from Alzheimer's to no­tice?

Last week
R&D

Strug­gling Adap­ti­m­mune gets a boost from the FDA as T cell can­cer drug wins an in­side track at the agency

Last week
R&D

Sen­ate com­mit­tee backs Stephen Hahn as the next FDA com­mis­sion­er

Last week
People
Regulatory

On the heels of $225M roy­al­ty deal, Ko­di­ak shoots for $250M raise to fund piv­otal pro­grams of its Eylea slay­er

Last week
Venture

FDA ush­ers Mer­ck­'s star can­cer drug Keytru­da to­ward an­oth­er key check­point

Last week
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

Last week
Publisher's note

FDA fi­nal­izes guid­ance on adap­tive tri­al de­signs

Last week
Regulatory

Astel­las snags a gene ther­a­py up­start with $3B buy­out bid — in­spir­ing fore­casts of more M&A ahead

Last week
Deals

FDA to Lex­i­con: Yeah, that's still gonna be a no from us

Last week
Regulatory

In­cyte nabs pri­or­i­ty re­view for bile duct can­cer drug; Temasek shows in­ter­est in an­oth­er Wood­ford dar­ling — re­port

Last week
Protocols
First page Previous page 123456 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Stories
  • Don't Miss

Channels

  • R&D
  • Pharma
  • Venture
  • People
  • Startups
  • Regulatory
  • Deals
  • IPOs
  • China
  • Cell/Gene Tx
  • Bioregnum
  • Peer Review
  • Discovery
  • Outsourcing
  • AI
  • Special

More

  • Events
  • Webinars
  • Sponsored Posts
  • Biotech Voices
  • Advertise
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© 2019 — Endpoints Company

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Sign in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS by John Carroll & team — all the news at 11:30a ET

EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET